Mesoblast (MESO) EBITDA: 2014-2023
Historic EBITDA for Mesoblast (MESO) over the last 8 years, with Jun 2023 value amounting to -$43.4 million.
- Mesoblast's EBITDA rose 28.99% to -$43.4 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$10.3 million, marking a year-over-year increase of 53.45%. This contributed to the annual value of -$62.0 million for FY2025, which is 4.74% up from last year.
- Per Mesoblast's latest filing, its EBITDA stood at -$43.4 million for Q2 2023, which was down 481.57% from $11.4 million recorded in Q1 2023.
- Mesoblast's 5-year EBITDA high stood at $33.5 million for Q3 2019, and its period low was -$97.3 million during Q2 2021.
- Its 3-year average for EBITDA is -$11.6 million, with a median of $11.3 million in 2022.
- Examining YoY changes over the last 5 years, Mesoblast's EBITDA showed a top increase of 118.94% in 2021 and a maximum decrease of 3,928.91% in 2021.
- Quarterly analysis of 5 years shows Mesoblast's EBITDA stood at $18.0 million in 2019, then decreased by 6.61% to $16.8 million in 2020, then fell by 16.44% to $14.0 million in 2021, then decreased by 25.32% to $10.5 million in 2022, then grew by 28.99% to -$43.4 million in 2023.
- Its last three reported values are -$43.4 million in Q2 2023, $11.4 million for Q1 2023, and $10.5 million during Q4 2022.